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Introduction
Thrombus formation in vivo is a dynamic process in which vascular injury initiates a cascade of events involving components of the vascular wall, platelets, other blood cells, and plasma proteins. Platelet activation and subsequent aggregation play a critical role in this process, especially in the high shear environment of the arterial circulation. While many of the agonists and receptors responsible for platelet activation have been identified, much less is known about post-aggregation signaling events that regulate thrombus growth and stability so that the optimal hemostatic response occurs. There is, however, ample reason to believe that such mechanisms exist and are essential for normal hemostasis. Several examples of post-aggregation platelet signaling have been described in recent years, including outside-in signaling through the integrin, a IIb b 3 [1] , continuous ADP receptor signaling [2, 3] , and contact-dependent signaling via platelet surface receptorligand interactions [4] [5] [6] [7] . Each of these signaling mechanisms has been shown to enhance the stability of platelet aggregates in vitro and in vivo.
In addition to these signaling molecules, platelets express several immunoglobulin superfamily proteins on their surface known to form homotypic interactions in trans between adjacent cells. Among these are the proteins PECAM-1 and CEACAM1, two immunotyrosine based inhibitory motif (ITIM) containing receptors [8, 9] . Both of these proteins have been characterized as negative regulators of platelet function because genetic deletion of either protein results in enhanced thrombus formation in vivo [8, 9] . Interestingly, platelets also express four members of the CTX family of adhesion molecules, junctional adhesion molecule-A (JAM-A) [10] , JAM-C [11] , endothelial cell specific adhesion molecule (ESAM) [12] and DNAM-1 (CD226) [13] , which also mediate interactions in trans between adjacent cells. Unlike PECAM-1 and CEACAM1, this family of proteins does not contain ITIM domains in their cytoplasmic tails. Whether these proteins mediate platelet-platelet interactions and/or contribute to postaggregation signaling events that regulate thrombus growth and stability has not been previously studied.
ESAM, which is the subject of this report, is a 55 kDa type I membrane glycoprotein with two extracellular immunoglobulin domains (one V-type and one C2), a single transmembrane domain and a long cytosolic tail that terminates in a type-I PDZ domain ligand [14] . When originally cloned, ESAM was shown to be expressed specifically by endothelial cells in diverse parts of the circulation [12, 14] , and by megakaryocytes and platelets [12] . Immunofluorescence studies show that ESAM accumulates at cell junctions in transfected cell lines as well as in endothelial cells, where it co-localizes with tight junction proteins [14, 15] . Further, ESAM mediates cell clustering via homophilic interactions when expressed in CHO cells [14] .
In light of these findings, ESAM was originally characterized as an adhesion molecule. However, generation of ESAMdeficient mice revealed that loss of ESAM from endothelial cell junctions results in increased junctional stability [16] . These findings suggest that rather than contributing adhesive strength to cell contacts, ESAM has a role in the coordinated destabilization of junctions in response to stimuli. In endothelial cells, this role for ESAM was demonstrated to be important for the transmigration of leukocytes [16] . The function of ESAM on platelets has not been previously examined, although studies have demonstrated that ESAM is stored in alpha granule membranes of resting platelets [17] , and accordingly its surface expression increases following platelet activation [12] . In addition, a recent study in zebrafish demonstrated that morpholino-mediated knockdown of ESAM expression results in enhanced thrombus formation following laser injury in vivo [18] .
In the present study we asked whether ESAM has a role in thrombus formation. The results show that: (i) ESAM concentrates at the junctions between platelets following platelet activation; to our knowledge this is the first demonstration of a cell adhesion molecule localizing to plateletplatelet contacts; (ii) ESAM-deficient mice achieve more stable hemostasis following tail transection and show increased platelet accumulation and fibrin formation following laser injury in vivo; (iii) platelets from ESAM-deficient mice aggregate at lower agonist concentrations and the aggregates that form are more stable than wild-type platelets; and (iv) fibrin clot retraction is delayed in the absence of ESAM. Taken together, these findings suggest that following platelet activation, ESAM localizes to areas of platelet-platelet contact in order to limit the extent of thrombus formation following vascular injury. To identify the molecular mechanism by which ESAM regulates platelet function we performed a PDZdomain library screen and identified a scaffold protein, NHERF-1, that interacts with the ESAM cytoplasmic tail in vitro and associates with ESAM in platelets.
The generation of ESAM-deficient mice was described previously [19] . They have been backcrossed on to a C57Bl/6 background for five generations. Mice used for the current studies (ESAM +/+ and
) were generated from homozygous crosses of parents obtained from heterozygous crosses. The Institutional Animal Care and Use Committee (IACUC) of the University of Pennsylvania approved all mouse studies.
Platelet preparation
Human platelets Whole blood was drawn from healthy volunteers according to the University of Pennsylvania Institutional Review Board guidelines, using ACD (65 mM trisodium citrate, 70 mM citric acid, 100 mM dextrose, pH 6.5) as the anticoagulant. Following centrifugation at 150 g to obtain platelet-rich plasma, the platelets were gel filtered over Sepharose 2B in a modified TyrodeÕs buffer (4 mM HEPES, pH 7.4, 135 mM NaCl, 2.7 mM KCl, 3.3 mM NaH 2 PO 4 , 2.4 mM MgCl 2 , 0.1% glucose and 0.1% BSA).
Mouse platelets Following anesthesia (90 mg kg )1 pentobarbital i.p.), mouse blood was drawn via cardiac puncture using heparin as the anticoagulant. The blood was diluted with an equal volume of TyrodeÕs buffer and centrifuged at 150 g to obtain platelet-rich plasma. Platelet counts were normalized to 2.5 · 10 8 platelets mL )1 using TyrodeÕs buffer.
Immunofluorescence Human gel-filtered platelets were activated with the PAR-1 agonist SFLLRN (10 lM) on microscope slides coated with 100 lg mL )1 fibrinogen for 25 min at 37°C. The platelets were then fixed (3.7% formaldehyde), permeabilized (0.2% Triton X-100), and blocked in 5% BSA followed by application of either anti-ESAM antiserum or rabbit pre-immune serum. The ESAM antiserum was generated using the ESAM extracellular domain (a.a. 30-248) as the immunogen (Covance Research Products, Denver, PA, USA). FITC-conjugated goat anti-rabbit antibody (Jackson Immunoresearch, West Grove, PA, USA) was used as a secondary reagent. Slides were visualized by confocal microscopy using a Zeiss LSM510 confocal microscope system (Carl Zeiss Microimaging, Inc. Thornwood, NY, USA).
Platelet aggregation Mouse platelet aggregation was performed as previously described using an optical aggregometer (Chronolog, Haverford, PA, USA) [20] . ; BD Bioscience, San Jose, CA, USA) and Alexa-647-labeled anti-fibrin antibodies (clone 59D8) [22] were administered via a catheter in the jugular vein to label platelets and fibrin, respectively. Arterioles of 30-50 lm in diameter were selected for study, and vascular injury was induced using a pulsed nitrogen dye laser fired through the microscope objective. Brightfield and fluorescent images were captured using a digital CCD camera (SensiCam, Cooke, Auburn Hills, MI, USA) coupled to Slidebook 4.2 image acquisition software (Intelligent Imaging Innovations, Denver, CO, USA). Up to 10 injuries were made in each mouse and three mice were studied in each group. Data are reported as the background-subtracted median integrated fluorescence intensity. Statistical analysis was performed using the MannWhitney test.
To determine the contribution of platelet ESAM vs. endothelial cell ESAM to thrombus formation using this model, we generated radiation chimera mice. Fetal liver cells were isolated from 16 to 18 d.p.c. wild-type or ESAM )/) fetuses and injected retro-orbitally into lethally irradiated male wildtype recipients (Cesium-137, 10 Gy, Gammacell 40 Exactor; MDS Nordion, Ontario, Canada). Intravital microscopy experiments were performed as described above 4 weeks after transplant. Hematopoietic reconstitution was confirmed by measuring platelet counts prior to intravital experiments.
Flow cytometric analysis of mouse platelets Mouse PRP was diluted in TyrodeÕs buffer to obtain a platelet concentration of 1 · 10 7 platelets mL )1
. Either FITC-labeled fibrinogen (100 lg mL Platelet calcium mobilization Washed mouse platelets pooled from two mice were loaded with Fura-2 (25 lg; Invitrogen) for 45 min at room temperature, followed by an additional wash in HEN buffer (10 mM HEPES, 150 mM NaCl and 1 mM EDTA, pH 6.5 plus 1 mM PGE 1 ) and finally resuspended in TyrodeÕs buffer. An Ôagonist plateÕ containing varying concentrations of platelet agonists was prepared on a Perkin Elmer Janus. Cytosolic calcium flux was measured at excitation 340/380 and emission 510 nm in high-throughput fashion using a Molecular Devices FlexStation (Sunnyvale, CA, USA). The 340/380 fluorescence ratio [R(t)] was scaled to the mean baseline value for each well [R 0 (t)] and relative calcium concentrations were quantified as R(t)/R 0 (t). All conditions were tested in replicates of eight.
Platelet spreading Washed ESAM +/+ or )/) platelets were stimulated with the PAR-4 agonist peptide AYPGKF (200 lM) and spread on immobilized fibrinogen (100 lg mL
) on a glass coverslip (No. 1.5). Platelets were visualized by reflection interference contrast microscopy using an inverted microscope (Axiovert 200; Karl Zeiss, Goettingen, Germany) with an antiflex 63 · oil immersion objective and appropriate polarizers. Images were recorded using a chargecoupled device camera (Retiga Exi Fast Cooled Mono 12-bit camera 32-0082B-128, QIMAGING, Burnaby, Canada).
Clot retraction Blood from ESAM
+/+ or )/) mice was drawn into sodium citrate (0.38% final concentration). Clot formation was induced by the addition of 10 U mL )1 thrombin (Haematologic Technologies, Inc., Essex Junction, VT, USA) at 37°C. Pictures were taken at 15, 30, 45 and 60 min following the addition of thrombin to visualize the extent of clot retraction. Retraction was quantified by determining the twodimensional area occupied by the clot using Slidebook 4.2 software, and is expressed as the percentage area (clot area/ total area*100).
PDZ domain array and co-immunoprecipitation A GST-ESAM fusion protein containing the c-terminal 30 amino acids of ESAM fused to GST was expressed in E. coli using the pGEX4k-T vector (GE Healthcare, Piscataway, NJ, USA), and affinity purified using glutathione sepharose. The GST-ESAM fusion protein was used to probe a PDZ domain array as previously described [23] . Bound GST-ESAM was detected with HRP-conjugated anti-GST antibody. In separate studies, ESAM was immunoprecipitated from human platelet lysates. Gel-filtered platelets were incubated with or without SFLLRN to activate platelets followed by lysis in 1% Triton X-100.
Lysates were incubated with anti-ESAM antibody to immunoprecipitate ESAM, and associated proteins were resolved by SDS-PAGE. An immunoblot was performed using an anti-NHERF-1 antibody (BD Biosciences) to demonstrate association of ESAM and NHERF-1 in platelets.
The reverse co-immunoprecipitation was also performed (immunoprecipitate NHERF-1 and blot for ESAM).
Statistical analysis Statistical analysis was performed using a two-tailed StudentÕs t-test unless otherwise noted.
Results

Localization of ESAM to platelet contacts
Nasdala et al. [12] previously demonstrated that ESAM is expressed on mouse platelets, and that its surface expression increases following platelet activation. We found similar results regarding ESAM expression in human platelets, including increased surface expression following platelet activation (Fig. 1A,B) . Immunofluorescence studies demonstrated that ESAM is distributed diffusely on isolated platelets spread on immobilized fibrinogen (Fig. 1C, panels i, ii) . Strikingly, when two or more platelets came in contact with each other ESAM became concentrated at the junction between the platelets. To our knowledge, this is the first demonstration of a cell adhesion molecule localizing to platelet-platelet contacts. Increased ESAM surface expression following activation, coupled with localization of ESAM at platelet-platelet contacts, suggests a role for ESAM in contact-dependent regulation of platelet function.
) mice were described previously [19] . Initial studies reported that they have normal platelet counts with no profound bleeding abnormalities, but have demonstrable defects in pathologic angiogenesis and leukocyte transmigration [16, 19] . To determine whether ESAM has a role in hemostasis in vivo, we assessed platelet function in ESAM )/) mice by measuring the tail bleeding time and by observing thrombus formation in the arteriolar microcirculation using intravital microscopy. We found no significant difference in the initial bleeding time between wild-type and ESAM )/) mice (117.5 ± 25.6 and 165.8 ± 35.7 s, respectively; mean ± SEM, P = 0.13), but re-bleeding occurred less frequently in the ESAM )/) mice. Our procedure involved cutting the distal 5 mm of the mouse tail, which resulted in only 10% of the tails from wild-type mice remaining stably occluded after 10 min ( Fig. 2A) . The remainder began re-bleeding 177 ± 29 s (mean ± SEM, n = 19) following the initial occlusion. In contrast, 29% of the transected ESAM )/) tails remained stably occluded and the average time until re-bleeding occurred in the remaining mice increased to 284 ± 49 s (P < 0.05 vs. WT, n = 14), indicating that ESAM )/) mice are more likely to form stable occlusions in this assay. Real time intravital digital microscopy was used to examine thrombus formation in vivo induced by laser injury to mouse cremaster muscle arterioles, as previously described [21] . Arteriolar wall shear rates were comparable in wild-type and ESAM-deficient mice (2116 ± 91 s , respectively). We examined both platelet accumulation and fibrin formation following laser injury. The kinetic profile of platelet accumulation was similar in wild-type and ESAM )/) mice, but the thrombi that formed were significantly larger in ESAM )/) mice (P < 0.05, Fig. 2B ,C). Initial fibrin accumulation was similar in the presence and absence of ESAM, but was significantly increased at later time-points during our observation period ( Fig. 2D , P < 0.05 after 180 s). To demonstrate that the observed effect on thrombus formation in vivo was not due to the loss of ESAM from endothelial cells, we generated chimeric mice by transplanting fetal liver cells from either wild-type or ESAM-deficient donors into lethally irradiated wild-type recipients. Chimeric mice lacking ESAM on their platelets, but with endothelial cell ESAM expression intact, formed larger thrombi in response to laser injury than chimeric mice that expressed ESAM on their platelets (Fig. 2E) . These results confirm that loss of ESAM from platelets is largely responsible for the observed increase in thrombus formation in ESAM-deficient mice using this thrombosis model. Thus, in two different models in which hemostasis was examined in vivo, thrombus formation was enhanced in mice lacking ESAM.
To determine the mechanism responsible for the enhanced thrombus formation observed in ESAM )/) mice in vivo, we examined the aggregation profile of platelets from ESAMdeficient mice in vitro. We found that aggregation of platelets lacking ESAM was consistently increased compared with their wild-type counterparts in response to sub-maximal concentrations of collagen, ADP and the PAR-4 agonist peptide, AYPGQV (Fig. 3) . This enhanced platelet aggregation was dependent on the integrin a IIb b 3 , as pretreatment of platelets with the a IIb b 3 antagonist tirofiban completely prevented aggregation of both wild-type and ESAM )/) platelets (data not shown). Notably, the enhanced aggregation in response to collagen was dependent on released ADP and thromboxane A 2 , as identical responses to collagen were observed in ESAM
and wild-type platelets following pretreatment with aspirin and the P2Y 12 antagonist cangrelor (data not shown). However, the enhanced platelet aggregation observed with ESAM
platelets stimulated with a PAR-4 agonist peptide was apparent even when secondary mediators (ADP and TxA 2 ) were inhibited (data not shown). Taken together, these results demonstrate that platelets lacking ESAM exhibit enhanced aggregation following stimulation of GPCR-dependent signaling pathways.
Effects on aggregate stability
Because thrombus stability was increased in ESAM )/) mice, we also examined the stability of platelet aggregates in the absence of ESAM. Recent studies have demonstrated that platelet aggregates can be induced to fall apart by interrupting ADP Laser-induced thrombus formation in radiation chimera mice expressing ESAM on their endothelium with or without ESAM expression on their platelets (n = 36 thrombi from 4 mice with wild-type platelets and n = 38 thrombi from four mice with ESAM-deficient platelets). extent as their wild-type counterparts when apyrase was added following peak aggregation (Fig. 4, left panel) . Similar results were obtained with tirofiban, which inhibits fibrinogen binding to a IIb b 3 (Fig. 4, right panel) . In both cases, these data demonstrate that platelets form more stable aggregates in the absence of ESAM.
To rule out a role for altered expression of other platelet surface proteins in the observed enhancement in thrombus formation in ESAM )/) mice, we used flow cytometry to measure expression levels of a IIb b 3 , GPIba, P-selectin and the ESAMrelated protein JAM-A. We found that surface expression of each of these proteins was similar on ESAM )/) and wild-type mouse platelets (Table 1) . Further, P-selectin expression following platelet activation was similar on ESAM )/) and wildtype platelets, demonstrating normal a-granule secretion in ESAM )/) mice (Table 1) . platelets as in wild-type controls (Fig. 5A) . Similarly, integrin activation measured using an antibody (JON/A) that is selective for the active conformation of a IIb b 3 did not differ between ESAM )/) and wild-type platelets over a range of agonist concentrations (50-500 lM AYPGKF; response to 500 lM AYPGKF is shown in Fig. 5B, left panel) . Similar results were obtained using FITC-labeled fibrinogen binding to measure a IIb b 3 activation (Fig. 5B, right panel) . Thus, the gain of function observed in the absence of ESAM in the platelet aggregation and in vivo thrombosis assays is not due to either increased Ca 2+ mobilization or a IIb b 3 activation.
Platelet spreading and clot retraction in ESAM )/) platelets
As calcium mobilization and integrin activation are unaffected in ESAM-deficient platelets, we next examined platelet spreading and clot retraction as measures of late platelet signaling events in the absence of ESAM. Platelet spreading on immobilized fibrinogen, a process dependent on a IIb b 3 out- side-in signaling, was indistinguishable in the presence and absence of ESAM (Fig. 6A,B) . In contrast, we found that fibrin clot retraction following thrombin stimulation is significantly delayed in the absence of ESAM (Fig. 6C,D) . Thus, ESAM is dispensable for platelet spreading, but appears to be necessary for efficient clot retraction, an event that involves post-aggregation signaling.
Interactions with the ESAM PDZ ligand domain
Finally, we sought to identify proteins that interact with ESAMÕs cytoplasmic tail as an alternative approach to determine the molecular mechanism by which ESAM regulates platelet function. The cytoplasmic domain of ESAM terminates in a type-I PDZ domain binding motif that is highly conserved across species (Fig. 7A) . The only known partner for ESAM is the PDZ domain containing protein MAGI-1 [15] , which we were unable to detect by Western blot in platelets (data not shown). To identify other potential ESAM interacting proteins, we generated a GST fusion protein containing the last 30 amino acid residues of the ESAM cytoplasmic tail, which includes the c-terminal PDZ domain binding motif. This fusion protein was used to probe a protein array containing 96 different PDZ domains from 48 different proteins [22] . We found that GST-ESAM bound to several PDZ domains on the array (Fig. 7B,C) . Among the proteins identified as interacting with ESAM on the array, only CAL and NHERF-1 were conclusively determined to be expressed in human platelets by Western blot analysis (Fig. 7D, top panel ). An association of ESAM and NHERF-1 was confirmed in both resting and activated platelets by co-immunoprecipitation using anti-ESAM to immunoprecipitate both proteins or by doing the reverse using anti-NHERF-1 as the immunoprecipitating antibody (Fig. 7D, bottom panel) . We were unable to demonstrate an association of ESAM and CAL in platelets (data not shown).
Discussion
Increasing evidence suggests that contact-dependent molecular interactions have an important physiological role in the maintenance of thrombus size and stability in vivo [24] . A diverse set of platelet surface proteins are involved in these events, including traditional signaling receptors such as G protein coupled receptors and receptor tyrosine kinases, as well as adhesive proteins such as a IIb b 3 . In the present study, we found that ESAM, one of several CTX-family members expressed on platelets, translocates to platelet-platelet contacts following platelet activation, suggesting a role for this protein in post-aggregation platelet functional events as well. ESAM was originally predicted to be an adhesion molecule, as it can bind to itself homophilically when expressed on adjacent cells [12, 14] , and it is found at tight junctions of endothelial cells [12] . Our finding that ESAM is localized to platelet-platelet contacts is consistent with these results. To our knowledge this is the first demonstration of a cell surface Functional significance of platelet ESAM 1893 molecule concentrating at platelet-platelet contacts, which points to a novel role for ESAM and possibly other CTXfamily members in platelet function. Interestingly, we found that platelet aggregates were more stable in the absence of ESAM in vitro and thrombi were larger and more stable in ESAM )/) mice in vivo. These findings are in agreement with a recent study demonstrating enhanced thrombus formation following morpholino-mediated knockdown of ESAM in zebrafish [18] . In addition, a similar gain of function phenotype is observed in JAM )/) mice [25] , suggesting that members of the CTX-family may have overlapping functions in platelets. Based on the finding that thrombus formation is increased in its absence, ESAM does not appear to contribute adhesive strength to platelet contacts, as might be expected for an adhesion molecule. This conclusion is consistent with recent findings regarding the function of ESAM on endothelial cells. Wegmann et al. demonstrated that VEGF-induced vascular permeability is significantly reduced in ESAM-deficient mice [16] (i.e. endothelial cell junctions are more stable in the absence of ESAM). They hypothesized that ESAM has a role in the coordinated disassembly of endothelial cell junctions in order to increase vascular permeability, possibly via effects on the small GTPase Rho. Similarly, Orlova et al. recently described an analogous role for the related protein, JAM-C, in the regulation of microvascular permeability via the small GTPase, Rap1 [26] . Taken together, these findings suggest that in both endothelial cells and platelets ESAM, as well as other CTXfamily members, contributes to signaling events that regulate the stability of cell-cell junctions. In endothelial cells, this process is critical in the regulation of both vascular permeability and leukocyte transmigration, while in platelets our data suggest that it is critical in the regulation of thrombus growth and stability. Despite the increase in aggregation, ESAM-deficient platelets did not have a demonstrable change in cytosolic calcium mobilization or the activation of a IIb b 3 . There are several possible explanations for these findings. First, as ESAM presumably depends on homophilic engagement of molecules on adjacent cells to exert its effects, any potential role in platelet signaling regulating integrin activation may not be apparent in the single cell suspensions in which the calcium and fibrinogen binding studies were performed. Second, given its initial localization in a-granules and subsequent localization at platelet contacts, it is likely that ESAM regulates platelet signaling events following integrin activation and engagement. To address this hypothesis, we examined the role of ESAM in platelet spreading and clot retraction, two functional events that occur following integrin ligand binding. The loss of ESAM has no effect on platelet spreading, although again these studies were performed in the absence of platelet-platelet interactions. In contrast, we found that fibrin clot retraction, a process previously demonstrated to be regulated by contact-dependent signaling events [27] , is significantly delayed in the absence of ESAM. It is unclear whether the effect of ESAM on clot retraction is mediated by a signaling pathway related to the one that is responsible for the observed effects on platelet aggregation, or whether these are independent signaling mechanisms both influenced by ESAM.
In this regard, the precise molecular mechanism by which ESAM regulates platelet function remains to be determined. The enhanced aggregation and thrombus formation in the ESAM knockout is reminiscent of the phenotype observed following the genetic deletion or antibody crosslinking of a growing list of platelet surface proteins that are considered negative regulators of platelet function, including PECAM-1 [8] , CEACAM1 [9] , and G6b-B [28] . However, the ESAM cytoplasmic tail does not contain ITIM domains (or any other phosphorylatable tyrosines), as described for these proteins [28] [29] [30] [31] , to explain its effects. It does, however, contain other potential protein interaction motifs. The ESAM cytoplasmic tail contains a proline-rich region that could bind SH3 domains and a c-terminal PDZ domain binding motif that is highly conserved across species, which suggests that recruitment of cytoplasmic proteins to the membrane is a likely mechanism by which it exerts its function. Accordingly, we have identified a PDZ domain containing scaffold protein, NHERF-1, that binds to the ESAM cytoplasmic tail in vitro and associates with ESAM in platelets. NHERF-1 contains two PDZ domains that interact with a diverse set of proteins, including GPCRs [32] , G proteins and PLCb [33] among others, as well as an ERMbinding domain that mediates interactions with components of the cytoskeleton [34] . Although additional studies are needed to definitively establish a role for NHERF-1 in the function of ESAM, the finding that ESAM accumulates at platelet contacts suggests a mechanism whereby ESAM may recruit NHERF-1 or other as yet unidentified cytoplasmic proteins to sites of platelet-platelet contact in order to regulate one or more key signaling pathways in platelets.
In conclusion, we have described a novel regulatory mechanism for the control of thrombus growth and stability involving the platelet membrane protein ESAM. These findings further advance our knowledge of the dynamic processes involved in platelet plug formation and stabilization, and future studies examining the relationship between ESAM, other CTX-family members and platelet signaling pathways may uncover a broader role for this family of cell adhesion molecules in platelet physiology. 
